Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5f56664f6-bqpqz Total loading time: 0 Render date: 2025-05-07T09:01:56.442Z Has data issue: false hasContentIssue false

11 - Hypertensive disorders of pregnancy

from Section 2 - Pregnancy, labor, and delivery complications causing brain injury

Published online by Cambridge University Press:  12 January 2010

By
Bonnie Dwyer  and
Deirdre J. Lyell
Edited by
David K. Stevenson ,
William E. Benitz ,
Philip Sunshine ,
Susan R. Hintz  and
Maurice L. Druzin
David K. Stevenson
Affiliation:
Stanford University School of Medicine, California
William E. Benitz
Affiliation:
Stanford University School of Medicine, California
Philip Sunshine
Affiliation:
Stanford University School of Medicine, California
Susan R. Hintz
Affiliation:
Stanford University School of Medicine, California
Maurice L. Druzin
Affiliation:
Stanford University School of Medicine, California
Get access

Summary

Introduction

Hypertensive disorders in pregnancy complicate up to 12–22% of all pregnancies and are the second leading cause of maternal deaths. They also contribute significantly to neonatal morbidity and mortality.

The National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy separates hypertensive disease in pregnancy into four categories: (1) chronic hypertension, (2) gestational hypertension, (3) pre-eclampsia, and (4) superimposed pre-eclampsia. This classification is an effort to create uniformity in diagnosis for diagnostic and research purposes. It is designed to describe distinct diseases with distinct pathophysiologies, and therefore distinct associated maternal and neonatal morbidity and mortality. However, hypertensive disease in pregnancy may represent a spectrum of disease, and thus the distinctions between these classifications can be blurred. This chapter will separately discuss chronic hypertension, gestational hypertension, and pre-eclampsia/superimposed pre-eclampsia and their known fetal effects. Treatment and intervention will also be discussed.

Fetal and neonatal effects of hypertension and pre-eclampsia are mainly due to alterations in placental perfusion, iatrogenic prematurity, and effects of maternal medications. In addition, there has been widespread interest in a controversial theory called the “Barker hypothesis.” This postulates that the intrauterine environment may program fetal physiology to be predisposed to specific adult diseases. Data used to support this theory include multiple retrospective studies which have correlated low birthweight (intrauterine growth restriction, IUGR) to multiple diverse adult diseases ranging from hypertension, coronary artery disease, and type 2 diabetes to depression and schizophrenia.

Type
Chapter
Information
Fetal and Neonatal Brain Injury , pp. 127 - 133
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

,American College of Obstetricians and Gynecologists. Practice Bulletin Number 29, July 2001. Chronic hypertension in pregnancy. In 2007 Compendium of Selected Publications, Volume II: Practice Bulletins. Washington, DC: ACOG, 2007: 609–17.
Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–22.
Boo, HA, Harding, JE. The developmental origins of adult disease (Barker) hypothesis. Aust NZ J Obstet Gynaecol 2006; 46: 4–14.CrossRefGoogle ScholarPubMed
Roberts, JM. Pregnancy-related hypertension. In Creasy, RK, Resnik, R, Iams, JD, eds., Maternal–Fetal Medicine: Principles and Practice, 5th edn. Philadelphia, PA: Saunders, 2004: 859–99.Google Scholar
,American College of Obstetricians and Gynecologists. Practice Bulletin Number 33, January 2002. Diagnosis and management of preeclampsia and eclampsia. In 2007 Compendium of Selected Publications, Volume II: Practice Bulletins. Washington DC: ACOG, 2007: 640–8.
Buchbinder, A, Sibai, BM, Caritis, S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186: 66–71.CrossRefGoogle ScholarPubMed
Lyell, DJ. Hypertensive disorders of pregnancy: relevance for the neonatologist. NeoReviews 2004; 5; e1–7.CrossRefGoogle Scholar
Saudan, P, Brown, MA, Buddle, ML, et al. Does gestational hypertension become pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 1177–84.CrossRefGoogle ScholarPubMed
Sibai, BM. Eclampsia, VI. Maternal–perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163: 1049–54.CrossRefGoogle ScholarPubMed
North, RA, Taylor, RS, Schellenberg, JC. Evaluation of a definition of pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 767–73.CrossRefGoogle ScholarPubMed
Sibai, BM. Pre-eclampsia. Lancet 2005; 365: 785–99.CrossRefGoogle ScholarPubMed
Sibai, BM, Barton, JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007; 196: 514.e1–9.CrossRefGoogle ScholarPubMed
Ness, RB, Sibai, BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gyncol 2006; 195: 40–9.CrossRefGoogle ScholarPubMed
Maynard, SE, Min, JY, Merchan, J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–58.CrossRefGoogle ScholarPubMed
Venkatesha, S, Toporsian, M, Lam, C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–9.CrossRefGoogle ScholarPubMed
Thadhani, R, Mutter, WP, Wolf, M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–5.CrossRefGoogle ScholarPubMed
Levine, RJ, Maynard, S, Qian, C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–83.CrossRefGoogle ScholarPubMed
Levine, RJ, Lam, C, Qian, C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 335: 992–1005.CrossRefGoogle Scholar
Sibai, BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004; 190: 1520–6.CrossRefGoogle ScholarPubMed
,American College of Obstetricians and Gynecologists. Practice Bulletin Number 43, May 2003. Management of preterm labor. In 2007 Compendium of Selected Publications, Volume II: Practice Bulletins. Washington, DC: ACOG, 2007: 688–96.
Resnik, R, Creasy, RK. Intrauterine growth restriction. In Creasy, RK, Resnik, R, Iams, JD, eds., Maternal–Fetal Medicine: Principles and Practice, 5th edn. Philadelphia, PA: Saunders, 2004: 495–512.Google Scholar
,American College of Obstetricians and Gynecologists. Practice Bulletin Number 12, January 2000. Intrauterine growth restriction. In 2007 Compendium of Selected Publications, Volume II: Practice Bulletins. Washington, DC: ACOG, 2007: 524–35.
Friedman, SA, Schiff, E, Kao, L, et al. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995; 172: 1785–92.CrossRefGoogle ScholarPubMed
Mittendorf, R, Dambrosia, J, Pryde, P, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002; 186: 1111–18.CrossRefGoogle ScholarPubMed
Crowther, CA, Hiller, JE, Doyle, LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669–76.CrossRefGoogle ScholarPubMed
,Magpie Trial Follow-up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007; 114: 289–99.
Cooper, WO, Hernandez-Diaz, S, Arbogast, PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443–51.CrossRefGoogle ScholarPubMed
Magee, , Cham, C, Waterman, EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327: 955–64.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×